Emerging evidence has proposed that EGFR TKI resistance operates through an integrin-mediated pathway [46,47], with some showing the increased involvement of FAK in the resistance of cancer cells to EGFR TKIs [48,49]. The gene discussed is EGFR; the disease is cancer.